Suppr超能文献

选定开菲尔发酵剂培养物的微生物群对胆固醇的体外摄取

In Vitro Cholesterol Uptake by the Microflora of Selected Kefir Starter Cultures.

作者信息

Ziarno Małgorzata, Zaręba Dorota, Ścibisz Iwona, Kozłowska Mariola

机构信息

Department of Food Technology and Assessment, Institute of Food Science, Warsaw University of Life Sciences-SGGW (WULS-SGGW), Nowoursynowska 159c St., 02-776 Warsaw, Poland.

Professor E. Pijanowski Catering School Complex in Warsaw, 04-110 Warsaw, Poland.

出版信息

Life (Basel). 2024 Nov 12;14(11):1464. doi: 10.3390/life14111464.

Abstract

Kefir, a fermented milk beverage, is recognized for its potential health benefits, including its cholesterol-lowering properties. This study demonstrated that selected kefir starter cultures, including strains and yeasts, significantly reduce cholesterol-binding capacity under simulated gastrointestinal conditions, underscoring the challenges of probiotic delivery. We compared the performance of these cultures under laboratory conditions (growth broths) and simulated digestive juice models. strains showed significant differences in cholesterol binding between the two environments, highlighting the limitations of relying solely on laboratory testing. Yeast cultures also exhibited greater cholesterol binding in their native broths, but their survival was limited in digestive models. Our findings suggest that effective probiotic formulations should prioritize strains with high cholesterol-binding capacity and robust survival rates throughout the digestive tract. This study provides valuable insights for future research on the mechanisms behind these functionalities and the potential of kefir yeast strains for use in human digestive models. Our results can be used to inform the development of improved probiotic formulations for cholesterol management.

摘要

开菲尔是一种发酵乳饮料,因其潜在的健康益处而受到认可,包括其降低胆固醇的特性。这项研究表明,选定的开菲尔发酵剂培养物,包括细菌菌株和酵母,在模拟胃肠道条件下显著降低胆固醇结合能力,凸显了益生菌递送的挑战。我们比较了这些培养物在实验室条件(生长肉汤)和模拟消化液模型下的性能。细菌菌株在两种环境之间的胆固醇结合方面表现出显著差异,突出了仅依赖实验室测试的局限性。酵母培养物在其原生肉汤中也表现出更强的胆固醇结合能力,但其在消化模型中的存活率有限。我们的研究结果表明,有效的益生菌制剂应优先选择具有高胆固醇结合能力且在整个消化道中具有强大存活率的菌株。这项研究为未来关于这些功能背后的机制以及开菲尔酵母菌株在人类消化模型中的应用潜力的研究提供了有价值的见解。我们的结果可用于为改善用于胆固醇管理的益生菌制剂的开发提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f979/11595744/4b09c1de6bf0/life-14-01464-g001.jpg

相似文献

5
A Non-yeast Kefir-like Fermented Milk Development with KCNU and Bmb6.利用KCNU和Bmb6开发一种非酵母类开菲尔发酵乳。
Food Sci Anim Resour. 2020 Jul;40(4):541-550. doi: 10.5851/kosfa.2020.e31. Epub 2020 Jul 1.

引用本文的文献

1
Trends in Microbiology 2024.《微生物学趋势》2024年
Life (Basel). 2025 Jan 8;15(1):65. doi: 10.3390/life15010065.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验